Phase III_Parsaclisib and Ruxolitinib_Myelofibrosis_INCB 50465-313 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
- Shah, Shilpan (PI)
- Ganguly, Siddhartha (Key Personnel)
- Petkova, Jenny (Key Personnel)
- Pingali, S. Ravi (Key Personnel)
- Rice, Lawrence (Key Personnel)
Project: Clinical Trial